EMD to Use Starpharma's Dendrimers for DNA and siRNA Transfection Research

Feb 22, 2007

NEW YORK (GenomeWeb News) — EMD Biosciences will use Starpharma’s dendrimers for DNA and siRNA transfection research, EMD said today.

Under the terms of the license and supply agreement, Starpharma’s US subsidiary Dendritic Nanotechnologies will supply EMD with the Priostar technology in exchange for royalties and milestones.

DNT will retain the full rights to use Priostarall for in vivo transfection research.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Make Sense of It All

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

Variations on Results

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

This Week in Nature

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

Of Many Minds

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Highly Resolved Separation of DNA Fragments on the Fragment Analyzer

How to Perform Successful CRISPR Experiments

High Throughput RT-qPCR for Gene Expression Analysis

Jun

19

Featured Webinar

RNA in situ Hybridization: The Next Generation of Immunohistochemistry?

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.

Main menu